Sialic Acid-Fibronectin–negative and CD-44–positive Pancreatic Cancer Has a Poor Prognosis Due To Epithelial-Mesenchymal Transition
Anticancer Research · 2026
DOI: 10.21873/anticanres.17965 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Takeshi Gocho und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, Jikei University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Pancreatic Neoplasms, Fibronectins, N-Acetylneuraminic Acid.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Surgery, Jikei University School of Medicine, Tokyo, Japan.
- Department of Breast, Thyroid, Endocrine Surgery, Jikei University School of Medicine, Tokyo, Japan; takeyama@jikei.ac.jp.
- Institute of DNA Sciences, Yokohama, Japan.
- Department of Breast, Thyroid, Endocrine Surgery, Jikei University School of Medicine, Tokyo, Japan.
Zitieren
APA
Gocho, T., Takeyama, H., Manome, Y., Tanaka, T., Matsumoto, M., Sakamoto, T., Yamashita, T., & Ikegami, T. (2026). Sialic Acid-Fibronectin–negative and CD-44–positive Pancreatic Cancer Has a Poor Prognosis Due To Epithelial-Mesenchymal Transition. Anticancer Research. https://doi.org/10.21873/anticanres.17965
Vancouver
Gocho T, Takeyama H, Manome Y, Tanaka T, Matsumoto M, Sakamoto T, et al. Sialic Acid-Fibronectin–negative and CD-44–positive Pancreatic Cancer Has a Poor Prognosis Due To Epithelial-Mesenchymal Transition. Anticancer Research. 2026. doi:10.21873/anticanres.17965
BibTeX
@article{Gocho2026,
author = {Gocho, Takeshi and Takeyama, Hiroshi and Manome, Yoshinobu and Tanaka, Tomoyuki and Matsumoto, Michinori and Sakamoto, Taro and Yamashita, Takaaki and Ikegami, Toru},
title = {Sialic Acid-Fibronectin–negative and CD-44–positive Pancreatic Cancer Has a Poor Prognosis Due To Epithelial-Mesenchymal Transition},
journal = {Anticancer Research},
year = {2026},
doi = {10.21873/anticanres.17965}
}
EUVIMED